Incyte's (INCY) EVP and General Counsel Sold 4,100 Shares for $352,000

Motley Fool

Oct 15

Sheila A. Denton, EVP & General Counsel of Incyte, recently executed an option exercise and immediately sold 4,100 shares of common stock Incyte's top drug, ruxolitinib, is expected to lose ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2575245813"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575245813\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575245813?lang=en_US&edition=fundamental","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Fmisc-assets%2Finsider.png&op=resize&w=165&h=104","is_english":true,"pubTime":"2025-10-15 01:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575245813","market":"fut","top_or_hot":-1,"title":"Incyte's (INCY) EVP and General Counsel Sold 4,100 Shares for $352,000","media":"Motley Fool","content":"<div>\n<p>Sheila A. Denton, EVP & General Counsel of Incyte, recently executed an option exercise and immediately sold 4,100 shares of common stock\n\n\n\n\n\n\n\nIncyte's top drug, ruxolitinib, is expected to lose ...</p>\n\n<a href=\"https://www.fool.com/coverage/filings/2025/10/14/incyte-s-incy-evp-and-general-counsel-sold-4-100-shares-for-usd352-000/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Incyte's (INCY) EVP and General Counsel Sold 4,100 Shares for $352,000</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIncyte's (INCY) EVP and General Counsel Sold 4,100 Shares for $352,000\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-15 01:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/coverage/filings/2025/10/14/incyte-s-incy-evp-and-general-counsel-sold-4-100-shares-for-usd352-000/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sheila A. Denton, EVP & General Counsel of Incyte, recently executed an option exercise and immediately sold 4,100 shares of common stock\n\n\n\n\n\n\n\nIncyte's top drug, ruxolitinib, is expected to lose ...</p>\n\n<a href=\"https://www.fool.com/coverage/filings/2025/10/14/incyte-s-incy-evp-and-general-counsel-sold-4-100-shares-for-usd352-000/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"https://www.fool.com/coverage/filings/2025/10/14/incyte-s-incy-evp-and-general-counsel-sold-4-100-shares-for-usd352-000/","article_id":"2575245813","we_media_id":null,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Fmisc-assets%2Finsider.png&op=resize&w=165&h=104"],"rights":{"source":"fool_stock","url":"https://www.fool.com/coverage/filings/2025/10/14/incyte-s-incy-evp-and-general-counsel-sold-4-100-shares-for-usd352-000/","rn_cache_url":null,"customStyle":"","selectors":".main-contain, #article-page","filters":"#sticky-wrapper, .navigation, .article-page-end, .foot, .author-tagline, .author-inline, .footer, .soc-share, .wysiwyg, .related-content","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2575245813","pubTimestamp":1760462820,"columns":[],"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Sheila A. Denton, EVP & General Counsel of Incyte, recently executed an option exercise and immediately sold 4,100 shares of common stock. Incyte's top drug, ruxolitinib, is expected to lose patent-protected market exclusivity in 2028. This event involved exercising 599 options and the immediate sale of 4,100 shares on October 3, 2025, reflecting a routine administrative process rather than a discretionary open-market sale. The majority of shares sold were not directly related to the newly exercised options, indicating that the sale also drew from previously held common shares.How does the share sale compare to Denton's recent trading activity?The 4,100-share sale is notably larger than Denton's recent median trade size of 598.5 shares for administrative transactions from June 3, 2025, to October 3, 2025. It represents 13.37% of her direct holdings as of October 3, 2025. This proportion is higher than the typical 1.87% median.What was Denton's post-transaction direct ownership and its ","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4532":"文艺复兴科技持仓","EVP":"Eaton Vance Pennsylvania Municip","TTM":"塔塔汽车","BK4550":"红杉资本持仓","INCY":"因塞特医疗","BK4588":"碎股","BK4099":"汽车制造商","BK4585":"ETF&股票定投概念","BK4523":"印度概念","BK4139":"生物科技"},"translate_title":"Incyte(INCY)执行副总裁兼总法律顾问以352,000美元出售4,100股股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVP":1.5,"INCY":1.5,"TTM":1},"content_text":"Sheila A. Denton, EVP & General Counsel of Incyte, recently executed an option exercise and immediately sold 4,100 shares of common stock\n\n\n\n\n\n\n\nIncyte's top drug, ruxolitinib, is expected to lose patent-protected market exclusivity in 2028\n\nOn October 2 and October 3, 2025, Sheila A. Denton, EVP & General Counsel of Incyte (INCY -0.14%), executed an option exercise and immediately sold 4,100 shares of common stock, as disclosed in this SEC Form 4 filing.Transaction summaryMetricValueShares sold4,100Shares withheldN/ATransaction value~$352,000Post-transaction shares26,569Post-transaction value (direct ownership)~$2.3 millionTransaction value calculated using the SEC Form 4 weighted average purchase price ($85.85) as of the transaction date (October 3, 2025); Post-transaction value calculated using the SEC Form 4 weighted average purchase price ($85.85).Key questionsWhat is the significance of the derivative context in this transaction?This event involved exercising 599 options and the immediate sale of 4,100 shares on October 3, 2025, reflecting a routine administrative process rather than a discretionary open-market sale. The majority of shares sold were not directly related to the newly exercised options, indicating that the sale also drew from previously held common shares.How does the share sale compare to Denton's recent trading activity?The 4,100-share sale is notably larger than Denton's recent median trade size of 598.5 shares for administrative transactions from June 3, 2025, to October 3, 2025. It represents 13.37% of her direct holdings as of October 3, 2025. This proportion is higher than the typical 1.87% median.What was Denton's post-transaction direct ownership and its value?Following this transaction, Denton held 26,569 shares directly, with an approximate market value of ~$2.3 million as of the October 3, 2025, close, with her direct ownership now at 0.0136% of outstanding shares.What is the broader market and company context for this trade?Incyte shares delivered a 29.5% one-year return. The company operates in the biotechnology sector with $4.58 billion in trailing twelve-month revenue and $870.9 million in trailing twelve-month net income, headquartered in Wilmington, Delaware, and employing 2,617 people as of the most recent data.Company overviewMetricValueRevenue (TTM)$4.58 billionNet income (TTM)$870.87 millionEmployees2,6171-year price change29.50%Note: 1-year price change calculated as of October 3, 2025, using a calendar-year window.Company snapshotKey products include JAKAFI for myelofibrosis and polycythemia vera, PEMAZYRE for various tumors, and ICLUSIG for leukemia; the company also has a robust pipeline with multiple clinical-stage assets targeting oncology and hematology indications.Incyte generates revenue primarily through the development, commercialization, and licensing of proprietary therapeutics, leveraging strategic collaborations with global pharmaceutical partners.Incyte is a biotechnology company specializing in the discovery and commercialization of therapeutics for oncology and hematology. With a strong portfolio of marketed products and a diverse pipeline, the company leverages strategic partnerships to accelerate development and broaden market reach.Foolish takeWatching insiders is a great way to know if a stock is a smart buy, but minor stock sales like this one don't tell us much. There are a million reasons for an insider to sell a stock that have nothing to do with the direction of the business they work for. For example, plenty of insiders sell shares to cover their children's college tuition bills around this time of year.Incyte shareholders are more than a little frustrated with the stock's performance. It's down by 12.7% over the past five years. The iShares U.S. Pharmaceuticals ETF has risen 29%, and the benchmark S&P 500 is up by 90% over the same time frame.In the second quarter, Incyte reported sales that grew 16% year over year to reach $1.2 billion. Unfortunately, its lead drug, ruxolitinib, is expected to lose patent-protected market exclusivity in 2028. That could be a huge patent cliff to overcome. Ruxolitinib, which Incyte markets under the brand names Jakafi and Opzelura, is responsible for 88% of product sales.GlossaryOption exercise: The act of converting stock options into actual shares of company stock, typically by paying an exercise price.Form 4: A required SEC filing that discloses insider trades of company securities by officers, directors, or major shareholders.Derivative context: Refers to transactions involving financial instruments like options, whose value is derived from underlying assets such as company stock.Administrative transaction: A routine, often pre-scheduled, insider transaction not based on discretionary investment decisions.Direct ownership: Shares held personally by an individual, not through trusts, funds, or indirect means.Outstanding shares: The total number of a company's shares that are currently owned by all shareholders, including insiders and the public.Weighted average purchase price: The average price paid per share in a transaction, weighted by the number of shares at each price.Clinical-stage assets: Drug candidates currently being tested in human clinical trials, but not yet approved for sale.Strategic collaborations: Partnerships between companies to jointly develop, market, or commercialize products or technologies.TTM: The 12-month period ending with the most recent quarterly report.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}